← Leaderboards
D. Noah Sather
Seattle Children'S Hospital
$18,678,273
Attributed
$26,056,182
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,056,182 · 11
By mechanism
R01$22,191,394 · 7
U19$1,683,227 · 2
R33$1,653,392 · 1
R21$528,169 · 1
Top collaborators
- Donald L Sodora9 shared
- Stefan H.I. Kappe7 shared
- Jeremy V. Smedley3 shared
- Kristian Edward Swearingen2 shared
- Jean-Philippe Julien1 shared
Most similar at Seattle Children'S Hospital
Same institution · by research overlap
- Donald L Sodora$27,419,798
- Rachel Adria Katzenellenbogen$5,972,941
- Jeremy V. Smedley$1,735,389
- Kenneth D Stuart$53,231,777
- Stefan H.i. Kappe$29,220,139
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesAntigensInfectionImmunityImmune ResponseVaccinationAntibodiesResponseVaccine DevelopmentVaccine CandidateNeutralizing AntibodyDesignSurfaceCessation Of LifePreventImmunizationMediatingImmunogenicityNext GenerationExhibitsTransmission ProcessRegimenAntibody ResponseHiv-1
Grant awards (35)
Defining the immunogenic landscape of early mosquito-stage P. falciparum to accelerate malaria transmission-blocking vaccine discovery$947,948
R01 · FY2025 · AI
Species-transcending prevention of mosquito vector infection$832,071
R01 · FY2025 · AI · contact PI
Influence of viral and immune interventions on early events following oral SIV infection$797,333
R01 · FY2025 · DE
Defining the immunogenic landscape of early mosquito-stage P. falciparum to accelerate malaria transmission-blocking vaccine discovery$969,948
R01 · FY2024 · AI
Influence of viral and immune interventions on early events following oral SIV infection$791,082
R01 · FY2024 · DE
Influence of viral and immune interventions on early events following oral SIV infection$957,147
R01 · FY2023 · DE
Kinetics, evolution, and effector function of Fc repertoires during vaccination with native-like Env trimers$856,679
R01 · FY2023 · AI · contact PI
Development of a pre-erythrocytic P. vivax vaccine to prevent clinical relapse$822,542
R01 · FY2023 · AI · contact PI
Kinetics, evolution, and effector function of Fc repertoires during vaccination with native-like Env trimers$877,375
R01 · FY2022 · AI · contact PI
Development of a pre-erythrocytic P. vivax vaccine to prevent clinical relapse$822,542
R01 · FY2022 · AI · contact PI
Kinetics, evolution, and effector function of Fc repertoires during vaccination with native-like Env trimers$890,180
R01 · FY2021 · AI · contact PI
Development of a pre-erythrocytic P. vivax vaccine to prevent clinical relapse$822,542
R01 · FY2021 · AI · contact PI
Kinetics, evolution, and effector function of Fc repertoires during vaccination with native-like Env trimers$890,180
R01 · FY2020 · AI · contact PI
Infection-blocking antibody targets for malaria$826,064
R01 · FY2020 · AI
Development of a pre-erythrocytic P. vivax vaccine to prevent clinical relapse$822,542
R01 · FY2020 · AI · contact PI
Harnessing oral mucosa vaccination to drive protective HIV antibody responses$718,084
R01 · FY2020 · DE
Kinetics, evolution, and effector function of Fc repertoires during vaccination with native-like Env trimers$912,255
R01 · FY2019 · AI · contact PI
Infection-blocking antibody targets for malaria$845,571
R01 · FY2019 · AI
Development of a pre-erythrocytic P. vivax vaccine to prevent clinical relapse$844,617
R01 · FY2019 · AI · contact PI
Harnessing oral mucosa vaccination to drive protective HIV antibody responses$828,617
R01 · FY2019 · DE
Harnessing oral mucosa vaccination to drive protective HIV antibody responses$685,700
R01 · FY2018 · DE
Infection-blocking antibody targets for malaria$455,999
R01 · FY2018 · AI
Infection-blocking antibody targets for malaria$393,856
R01 · FY2018 · AI
Harnessing oral mucosa vaccination to drive protective HIV antibody responses$170,188
R01 · FY2018 · DE
Harnessing oral mucosa vaccination to drive protective HIV antibody responses$855,888
R01 · FY2017 · DE
Infection-blocking antibody targets for malaria$850,549
R01 · FY2017 · AI
Harnessing oral mucosa vaccination to drive protective HIV antibody responses$853,346
R01 · FY2016 · DE
Infection-blocking antibody targets for malaria$850,549
R01 · FY2016 · AI
Preclinical Evaluation of Envelope Immunogens Optimized to Elicit VRCOI-class An$1,463,174
U19 · FY2014 · AI · contact PI
Novel HIV 1 Envelope immunogens derived from broadly neutralizing plasmas$566,919
R33 · FY2014 · AI · contact PI
Envelope Immunogen and Recombinant Antibody Production Core$220,053
U19 · FY2014 · AI · contact PI
Novel HIV 1 Envelope immunogens derived from broadly neutralizing plasmas$532,904
R33 · FY2013 · AI · contact PI
Novel HIV 1 Envelope immunogens derived from broadly neutralizing plasmas$553,569
R33 · FY2012 · AI · contact PI
Novel HIV 1 Envelope immunogens derived from broadly neutralizing plasmas$264,460
R21 · FY2011 · AI · contact PI
Novel HIV 1 Envelope immunogens derived from broadly neutralizing plasmas$263,709
R21 · FY2010 · AI · contact PI